The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Warning! GuruFocus has detected 1 Warning Sign with MRK. A pillar of Merck's portfolio, Keytruda, sometimes known as pembrolizumab, brought in $21.6 billion in income in the first nine months of ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others .Key Merkel Cell ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Cancer patients to receive relief on imported medicines through Basic Customs Duty exemptions and patient assistance programmes.